1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Gerresheimer AG
  6. News
  7. Summary
    GXI   DE000A0LD6E6

GERRESHEIMER AG

(GXI)
  Report
Delayed Xetra  -  11:35 2022-08-17 am EDT
59.40 EUR   -1.41%
08/17GERRESHEIMER AG : Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source
EQ
08/17Gerresheimer and Zollner Enter into A Strategic Partnership for Electronically Controlled Medtech Systems from A Single Source
CI
08/10GERRESHEIMER AG : Buy rating from Deutsche Bank
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gerresheimer and Portal Enter Strategic Partnership to Treat Chronically Ill Patients with Innovative Needle-Free Drug-Delivery Solution

05/09/2022 | 08:56am EDT

Gerresheimer AG announced an investment into US-based Portal Instruments, a developer of a next-generation needle-free drug delivery technology. Together, the partners aim at transforming the administration of injectable medicines and improving the patient's experience, especially for those with chronic diseases. Portal develops technology which allows for needle-free and high-speed subcutaneous injection of medicine and –via connectivity – the adherence monitoring along the treatment journey by patient and medical care provider. Portal Instruments is based in Cambridge, Massachusetts, and has its roots in MIT'sBio Instrumentation Lab. Portal's needle-free injector and cartridge are components of a drug delivery platform for both biologics and biosimilars, completed and made available through biopharma partners. While many auto injectors on the market require patients to hold the needle onto their skin for 10 to 30 seconds, Portal's needle-free device can inject the same volume in less than a second. At the same time, this innovative type of injection helps to reduce painduring the application. And the injector is more than a drug delivery system: Thanks to its connectivity, adherence tracking, and customizable disease management becomes possible for both patient and medical care provider. Gerresheimer will support the development of the new technology, take part in manufacturing the reusable injector and supply cartridges containing the medicine.


© S&P Capital IQ 2022
All news about GERRESHEIMER AG
08/17GERRESHEIMER AG : Gerresheimer and Zollner enter into a strategic partnership for electron..
EQ
08/17Gerresheimer and Zollner Enter into A Strategic Partnership for Electronically Controll..
CI
08/10GERRESHEIMER AG : Buy rating from Deutsche Bank
MD
08/09GERRESHEIMER : invests up to 94 million Dollar in US production facility
PU
08/09GERRESHEIMER AG : Gerresheimer invests up to 94 million Dollar in US production facility
EQ
08/09Gerresheimer Invests Up to $94 Million in US Production Facility
CI
07/26GERRESHEIMER : focuses on sustainable glass production
PU
07/18GERRESHEIMER AG : Notification and public disclosure of transactions by persons
EQ
07/14GERRESHEIMER AG : Gets a Buy rating from Credit Suisse
MD
07/14GERRESHEIMER AG : Deutsche Bank gives a Buy rating
MD
More news
Analyst Recommendations on GERRESHEIMER AG
More recommendations
Financials
Sales 2022 1 713 M 1 742 M 1 742 M
Net income 2022 111 M 113 M 113 M
Net Debt 2022 1 070 M 1 088 M 1 088 M
P/E ratio 2022 16,9x
Yield 2022 2,24%
Capitalization 1 865 M 1 897 M 1 897 M
EV / Sales 2022 1,71x
EV / Sales 2023 1,58x
Nbr of Employees 10 803
Free-Float 100%
Chart GERRESHEIMER AG
Duration : Period :
Gerresheimer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 59,40 €
Average target price 88,69 €
Spread / Average Target 49,3%
EPS Revisions
Managers and Directors
Dietmar Siemssen Chief Executive Officer
Bernd Metzner Chief Financial Officer
Axel Herberg Chairman-Supervisory Board
Theodor Stuth Member-Supervisory Board
Udo Johannes Vetter Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
GERRESHEIMER AG-29.87%1 925
ABBOTT LABORATORIES-21.45%196 189
MEDTRONIC PLC-8.26%126 639
BECTON, DICKINSON AND COMPANY7.51%76 370
HOYA CORPORATION-12.97%39 454
SARTORIUS STEDIM BIOTECH-17.41%36 666